Loading company…
ID 212153667 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პრეპარატების წარმოება.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 0 | -622 | 7,660 | 8,609 | 9,951 | 9,090 | 7,425 | nmf |
| Net Cash used in Investing Activities | 0 | -131 | -7,413 | -7,408 | -10,006 | -9,194 | -7,192 | +122.9% |
| Free Cash Flow (OCF − Capex proxy) | 0 | -753 | 248 | 1,201 | -55 | -105 | 233 | nmf |
| Net Change in Cash (before FX) | 0 | -753 | 248 | 1,201 | -55 | -105 | 233 | nmf |
| Effect of FX on Cash | 0 | 0 | 45 | -35 | -290 | -94 | -62 | nmf |
| Net Change in Cash (incl. FX) | 0 | -753 | 293 | 1,165 | -345 | -199 | 171 | nmf |
| Cash at Beginning of Year | 912 | 932 | 179 | 471 | 1,637 | 1,292 | 1,093 | +3.1% |
| Cash at End of Year | 912 | 179 | 471 | 1,637 | 1,292 | 1,093 | 1,264 | +5.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).